The maker of the allergy drug EpiPen racked up an increasing amount of money from taxpayer-funded government programs over the past five years, Sen. Chuck Grassley says.

The share of Mylan’s revenue from government programs such as Medicaid and Medicare rose 30 percentage points from 23.3 percent in 2011 to 53.4 percent in 2015, the Iowa Republican’s office found.

Recommended Stories

Major companies abandon SPLC’s ‘hate groups’ screening tool in corporate giving programs

Here are the messages that could decide the midterm elections as campaigns make their final pitches

Don’t send an army to Haiti. Command the allies and algorithms that will protect the Shield of the Americas